Gastric cancer remains a formidable clinical challenge worldwide, attributed largely to its aggressive nature and resistance to conventional therapies. Scientists have long sought to identify molecules capable of curbing tumor growth and metastasis without incurring debilitating side effects. This study centers on quercetin, a compound richly found in fruits and vegetables, that has demonstrated promising anti-cancer properties in various malignancies but whose exact mechanisms in gastric cancer were previously unclear.

The investigative team employed two human gastric cancer cell lines—AGS and MKN-45—to model the disease environment in vitro. These cells were treated with quercetin alongside well-established chemotherapeutic agents paclitaxel and cisplatin to provide a comparative framework for efficacy. The post-treatment analyses were comprehensive, assessing cellular viability, apoptosis, cell cycle disruption, migration, and invasive potential.

Quantitative techniques revealed that quercetin significantly diminished cell viability across both GC cell lines, paralleling the effects observed with paclitaxel and cisplatin. Flow cytometric assays substantiated these findings by demonstrating an increase in programmed cell death and notable cell cycle arrest. Additionally, the flavonoid impaired the cells’ intrinsic capabilities to invade and migrate, two hallmarks of metastatic potential. These functional bioassays provided compelling evidence of quercetin’s multi-modal anti-tumor activity.

At the molecular level, the researchers zoomed in on a metabolic cascade associated with immune evasion and tumor progression—tryptophan catabolism via the indoleamine 2,3-dioxygenase 1 enzyme (IDO1). Dysregulation of this enzymatic pathway leads to the accumulation of kynurenine, a metabolite known to activate the aryl hydrocarbon receptor (AhR), fostering an immunosuppressive microenvironment conducive to cancer growth.

Advanced gene and protein expression analyses demonstrated a coordinated downregulation of IDO1, its paralog IDO2, tryptophan 2,3-dioxygenase (TDO), kynurenine 3-monooxygenase (KMO), and AhR following treatment with quercetin. This concerted suppression disrupted the metabolic axis, potentially reinstating immune surveillance mechanisms and inhibiting oncogenic signaling pathways modulated by AhR activation.

The study’s findings hold significant translational implications. By attenuating the IDO1-Kynurenine-AhR axis, quercetin not only hampers the intrinsic proliferative and migratory capacities of gastric cancer cells but may also reprogram the tumor microenvironment towards a less permissive state. This dual action underscores the flavonoid’s potential as a complementary or alternative therapeutic agent, especially for patients who experience adverse effects from standard chemotherapy.

Comparative analysis showed that quercetin’s efficacy paralleled traditional chemotherapeutic drugs in several key aspects, yet it is presumed to carry a more favorable toxicity profile, given its dietary origin and established safety in humans. The study advocates further preclinical and clinical assessments to verify dosing regimens, bioavailability, and combinational strategies that include quercetin for optimal patient outcomes.

Moreover, the research invites a broader reconsideration of targeted metabolic pathways in oncology. Tryptophan metabolism and AhR signaling have emerged as critical nodes in cancer biology, interfacing metabolism, immunity, and cell behavior. Interventions like quercetin that can modulate these axes hold promise for undermining tumor resilience and enhancing immune-mediated clearance.

The methodology employed in this research exemplifies rigorous cellular and molecular interrogation. CCK-8 assays quantified cell viability changes, while flow cytometry enabled precise measurement of apoptosis rates and cell cycle alterations, providing mechanistic insights at the cellular level. The wound healing and Transwell assays served to quantify migration and invasion respectively, critical functional parameters linked to metastatic competence.

Molecular interrogation was conducted using quantitative PCR and Western blotting, tools that quantified gene transcription and protein translation of targeted enzymes and receptors within the tryptophan metabolism pathway. This multi-layered approach ensured robustness of conclusions, revealing quercetin’s capacity to suppress mRNA and protein levels synchronously.

The novelty of this study lies in identifying quercetin as a modulator of the IDO1-Kynurenine-AhR axis specifically in gastric cancer—a pathway previously implicated predominantly in immune regulation but now underscored as a direct influencer of aggressive tumor phenotypes. By delineating this link, the authors pave the way for a novel class of therapeutics aimed at metabolic reprogramming.

Further exploration into the pharmacodynamics and pharmacokinetics of quercetin will be vital to translate these promising in vitro findings into clinically effective interventions. The modulation of the tryptophan metabolism axis by flavonoids may extend beyond gastric cancer, opening vistas for cross-cancer therapeutic strategies exploiting metabolic vulnerabilities.

The potential integration of quercetin into combinatorial treatment regimens, possibly enhancing the efficacy of existing chemotherapeutic agents while mitigating their side effects, could revolutionize the management pipeline. Precision targeting of metabolic enzymes may overcome treatment resistance, a frequent barrier to successful cancer control.

In summation, this research heralds a promising horizon in oncological therapeutics where naturally derived compounds like quercetin can exert profound anti-cancer effects by targeting intricate metabolic and signaling networks. The suppression of the IDO1-Kynurenine-AhR axis emerges as a pivotal mechanism through which gastric cancer proliferation and migration can be restrained, offering hope for improved prognoses.

The implications extend beyond biological curiosity, touching on the clinical promise of integrating dietary phytochemicals into the armamentarium against one of the deadliest cancers globally. As the scientific community intensifies its focus on tumor metabolism, studies such as this underscore the necessity of holistic approaches marrying natural compounds with precision oncology.

Subject of Research: Gastric cancer cell proliferation and migration inhibition via modulation of IDO1-mediated tryptophan metabolism.

Article Title: Quercetin inhibits gastric cancer cell proliferation and migration and is associated with the suppression of the IDO1-Kynurenine-AhR axis.

Article References: Zhu, M., Hu, Q., Lu, Y. et al. Quercetin inhibits gastric cancer cell proliferation and migration and is associated with the suppression of the IDO1-Kynurenine-AhR axis. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15308-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15308-0

Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide, owing largely to its heterogeneity and the complexity of the underlying molecular pathways that drive tumor initiation, progression, metastasis, and resistance to conventional therapies. Traditional chemotherapy and targeted treatments often face challenges such as adverse side effects and the eventual development of drug resistance. Therefore, identifying agents that can concurrently modulate multiple oncogenic pathways can revolutionize breast cancer management. Quercetin’s pleiotropic effects make it a molecule of particular interest in this context.

The molecular architecture of quercetin allows it to interact with and influence a spectrum of cellular signaling pathways implicated in breast cancer. Its antioxidant properties enable it to mitigate oxidative stress—a known contributor to DNA damage and carcinogenesis. Beyond this, quercetin exhibits the ability to modulate critical regulators of cell proliferation and apoptosis, which are pivotal in maintaining cellular homeostasis. For example, the flavonoid effectively downregulates oncogenes while promoting tumor suppressor gene activity, orchestrating a balanced cellular environment that favors cancer cell death over survival.

One of the striking features of quercetin elucidated in the study is its impact on the PI3K/Akt/mTOR signaling pathway, a central node in cancer cell metabolism, growth, and survival. Dysregulation of this pathway is a hallmark of numerous breast cancer subtypes, including the notoriously aggressive triple-negative breast cancer. Quercetin’s inhibitory effect on this pathway curtails cell proliferation and sensitizes cancer cells to apoptosis. This dual action could serve as an adjunct to existing therapies, potentially overcoming resistance and reducing tumor aggressiveness.

Moreover, quercetin exerts profound effects on the NF-κB signaling cascade, a critical mediator of inflammation and cancer progression. Aberrant activation of NF-κB contributes to increased survival signaling and resistance to apoptosis, enabling cancer cells to thrive even under harsh conditions. By suppressing NF-κB, quercetin limits the inflammatory milieu conducive to tumor growth, effectively dampening the pro-tumorigenic microenvironment.

Importantly, the study underscores quercetin’s ability to modulate estrogen receptor (ER) signaling in hormone-responsive breast cancer types. Given that ER-positive breast cancers constitute a significant fraction of breast cancer diagnoses, the capacity to influence ER-mediated transcriptional programs provides a valuable therapeutic dimension. Quercetin interferes with ER signaling by downregulating ER expression and inhibiting downstream target genes, thereby attenuating cancer cell proliferation driven by estrogen.

Metastasis—the dissemination of cancer cells from the primary tumor to distant sites—is the leading cause of mortality in breast cancer patients. Quercetin’s role in inhibiting epithelial-mesenchymal transition (EMT), a key process enabling metastatic spread, represents a critical checkpoint in halting disease progression. The flavonoid impedes EMT by modulating the expression of adhesion molecules such as E-cadherin and influencing cytoskeletal organization, thus reducing the invasive and migratory capabilities of breast cancer cells.

In addition to these molecular mechanisms, quercetin’s influence extends to modulation of angiogenesis—the formation of new blood vessels which tumors exploit for nutrition and oxygen. By suppressing vascular endothelial growth factor (VEGF) expression and signaling, quercetin starves tumors of their blood supply, impairing growth and metastatic potential. This anti-angiogenic effect complements its other anticancer activities, showcasing the multifarious roles quercetin can assume in combating breast tumors.

The integration of quercetin into therapeutic regimens also involves its impact on cancer stem cells (CSCs), a subpopulation within tumors responsible for recurrence and treatment resistance. The study highlights how quercetin targets CSC-specific markers and signaling pathways, reducing the ability of these cells to self-renew and propagate the tumor mass. This strategic disruption of CSC biology could lead to longer-lasting treatment responses and improved patient outcomes.

Notably, quercetin enhances the efficacy of conventional chemotherapeutics by sensitizing breast cancer cells to drug-induced apoptosis. It achieves this by modulating efflux pumps and apoptotic regulators, reducing the development of multidrug resistance—a common obstacle in successful cancer chemotherapy. Combining quercetin with standard drugs could potentially lower the required doses of toxic chemotherapeutics, minimizing side effects and improving quality of life for patients.

However, despite the compelling in vitro and in vivo evidence supporting quercetin’s therapeutic potential, clinical translation remains a significant hurdle. The bioavailability of quercetin is inherently low due to poor solubility and rapid metabolism, warranting innovative delivery strategies. Nanoencapsulation and other advanced drug delivery technologies are being explored to overcome these challenges, ensuring that therapeutic concentrations can be achieved at tumor sites while minimizing systemic exposure.

Furthermore, safety profiles of quercetin are favorable, as it is generally regarded as a non-toxic dietary flavonoid. Nonetheless, comprehensive clinical trials are essential to establish optimal dosing regimens, pharmacokinetics, and potential interactions with existing breast cancer therapies. The study by Hjazi and colleagues calls for intensified clinical research efforts to validate quercetin’s efficacy and safety in human subjects.

The implications of this research extend beyond breast cancer, as quercetin’s multi-targeted actions suggest it could be efficacious against other malignancies characterized by similar dysregulated pathways. Such broad-spectrum activities underscore the importance of natural compounds as reservoirs of pharmacological potential worth harnessing in oncology.

Intriguingly, the study also touches upon the synergistic potential of quercetin when combined with other bioactive compounds and phytochemicals. These combinatorial regimens might yield enhanced anticancer effects by simultaneously targeting multiple tumorigenic processes, a prospect that invites further exploration into diet-based adjunct therapies.

In conclusion, the work of Hjazi et al. positions quercetin not merely as a supplement but as a promising candidate in the evolving landscape of breast cancer therapeutics. Its ability to modulate a plethora of molecular pathways characteristic of cancer pathobiology offers hope for more effective and less toxic treatment avenues. This study reinvigorates the dialogue around integrating nutraceuticals with mainstream oncology, emphasizing a future wherein natural compounds may coalesce with conventional treatments to deliver superior clinical outcomes.

As the scientific community continues to unravel the intricate molecular architecture of breast cancer, discoveries such as these illuminate the path toward precision medicine paradigms that marry efficacy with tolerability. Quercetin’s versatile modality exemplifies how nature-derived agents can fill critical voids in the oncology armamentarium, potentially transforming the prognosis for millions of breast cancer patients worldwide.

The momentum generated by this research underscores the urgency for interdisciplinary collaborations among molecular biologists, pharmacologists, and clinical oncologists to expedite quercetin’s journey from bench to bedside. It is within this nexus that novel therapeutic paradigms will emerge, offering renewed hope in the battle against breast cancer.

Subject of Research: Quercetin as a multi-targeted therapeutic agent in breast cancer, focusing on its molecular targets and therapeutic potential.

Article Title: Quercetin as a multi-targeted therapeutic agent in breast cancer: molecular targets and therapeutic potential.

Article References:
Hjazi, A., Mohammed, S.N., Abosaoda, M.K. et al. Quercetin as a multi-targeted therapeutic agent in breast cancer: molecular targets and therapeutic potential. Med Oncol 42, 365 (2025). https://doi.org/10.1007/s12032-025-02907-x

Image Credits: AI Generated